ClikSTAR Gets Approval In EU, Canada

Sanofi-Aventis has announced that ClikSTAR, a new reusable insulin pen, for administration of the 24-hour insulin analog Lantus (insulin glargine [rDNA] injection) or/and the rapid acting insulin analog Apidra (insulin glulisine [rDNA origin] injection), will be available in Europe and Canada in October 2009.

ClikSTAR, which has recently received regulatory approval in EU and Canada will be launched in Canada, Greece, the Netherlands, and Switzerland. It is designed to provide the performances of the SoloSTAR pen, in a reusable form.

ClikSTAR is currently being reviewed by the FDA. It is the new easy to use reusable pen for administration of Lantus and Apidra and all other Sanofi-Aventis insulins.

Jean-Philippe Santoni, SVP of industrial development and innovation at Sanofi-Aventis, said: “ClikSTAR is the result of over four years of intensive development and testing of pens, designed in close collaboration with patients and conceived to fulfill patients’ needs. The ClikSTAR delivery system is precise, easy to use and reliable, addressing both patients’ expectations and medical needs.”